How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

876 results for

Actinic Keratoses

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Rapidly-growing squamous cell carcinoma shortly after treatment with ingenol mebutate for actinic keratoses: report of 2 cases. Full Text available with Trip Pro

Rapidly-growing squamous cell carcinoma shortly after treatment with ingenol mebutate for actinic keratoses: report of 2 cases. Actinic keratoses (AKs) are defined as cutaneous areas of atypical squamous transformation that are regarded as an early step in the continuum of alterations leading from normal skin to invasive and metastatic squamous cell carcinoma (SCC). AKs are classified as precancerous lesions by some authors and in situ SCC by others. The rate of evolution of a given AK

2015 British Journal of Dermatology

82. Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses

Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses (IMOT001) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02473848 Recruitment Status : Terminated (Lack of enrolment) First Posted : June 17, 2015 Last Update Posted : July 19, 2018 Sponsor: Günther Hofbauer

2015 Clinical Trials

83. Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses

Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03327831 Recruitment Status : Completed First Posted : October 31, 2017 Last Update Posted : December 15, 2017 Sponsor: University of California, Irvine

2015 Clinical Trials

84. Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times

Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times - Full Text (...) View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy

2015 Clinical Trials

85. A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses

A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02520700 Recruitment Status : Completed First

2015 Clinical Trials

86. Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel

Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02647151 Recruitment Status : Unknown Verified January 2016 by Fundación

2015 Clinical Trials

87. Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol

Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02644187 Recruitment Status : Completed First Posted : December 31, 2015 Last Update Posted : May 10, 2017 Sponsor: Vastra

2015 Clinical Trials

88. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. (Abstract)

Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. This randomized, 3-group study compared the efficacy and tolerability of 3 treatment modalities for facial actinic keratoses.Twenty-four healthy adult male and female subjects who had 4 to 8 clinically visible and discrete actinic keratoses on the face in a contiguous 25cm2 treatment area. Subjects were randomized into one (...) of three treatment groups: 2 treatments with 5-aminolevulinic acid (ALA) and photodynamic therapy (PDT), 1 ALA-PDT treatment and 1 course of ingenol mebutate (ingenol mebutate) 0.015% gel daily for 3 consecutive days, or 1 course of ingenol mebutate gel alone. Actinic keratoses in the treatment field were counted at the baseline visit, and at the completion of the study (day 57 or day 71). At the site of application, local site reactions were graded at each visit.Subjects in the two ALA-PDT treatment

2015 Journal of drugs in dermatology : JDD Controlled trial quality: uncertain

89. Actinic Keratoses Treatment With Metvix® in Combination With Light

Actinic Keratoses Treatment With Metvix® in Combination With Light Actinic Keratoses Treatment With Metvix® in Combination With Light - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Actinic Keratoses (...) : University Hospital, Limoges Collaborator: Galderma Information provided by (Responsible Party): University Hospital, Limoges Study Details Study Description Go to Brief Summary: The main objective of this study is to compare efficacy and safety of Metvix® natural daylight photodynamic therapy with those of Metvix® conventional photodynamic therapy in subjects with mild actinic keratoses (intra-individual comparison) Condition or disease Intervention/treatment Phase Actinic Keratoses Drug: Metvix®

2015 Clinical Trials

90. Dermoscopy and reflectance confocal microscopy of pigmented actinic keratoses: a morphological study. (Abstract)

Dermoscopy and reflectance confocal microscopy of pigmented actinic keratoses: a morphological study. Actinic keratoses (AKs) are very common lesions on sun damaged skin and, when pigmented, represent a challenge in the differential diagnosis with early melanoma. Non-invasive diagnostic methods, such as dermoscopy and reflectance confocal microscopy (RCM) have been shown to improve the diagnostic accuracy of melanoma and non-melanoma skin cancer, however, only one case report described confocal

2015 Journal of the European Academy of Dermatology and Venereology

91. Guidelines for care of patients with actinic keratosis

of this set of recommendations is scheduled for 2021; where necessary, important interim changes will be updated on the BAD website. 6.0 Background Actinic keratoses (synonymous with solar keratoses) are kera- totic lesions occurring on chronically light-exposed adult skin. They represent focal areas of abnormal keratinocyte prolifera- tion and differentiation that carry a low risk of progression to invasive SCC. A spectrum of histology is seen, but the cardinal feature of an AK is epithelial dysplasia (...) . This may be restricted to the basal layer or may extend to full-thickness atypia, at which point the lesion is known as SCC in situ (Bowen dis- ease). There is disorderly arrangement and maturation of epithelial cells. Multiple buds of epithelial cells may occur at the membrane zone, but no invasion is seen. Histological vari- ants of AK have been described, including hypertrophic, bowenoid, lichenoid, acantholytic and pigmented. Actinic keratoses are generally considered to be premalig- nant lesions

2017 British Association of Dermatologists

92. An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (SK-FAN) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03487588 Recruitment Status : Completed First Posted : April 4, 2018 Last Update Posted : February 25, 2019 Sponsor

2018 Clinical Trials

93. Actinic keratosis: ingenol mebutate gel (ESNM14)

of actinic keratoses. British Journal of Dermatology 156: 222–230 European Dermatology Forum. (2011) Guideline on actinic keratoses European Medicines Agency (2012) European public assessment report: Picato Gupta AK, Paquet M, Villanueva E et al. (2012) Interventions for actinic keratoses. Cochrane Database of Systematic Reviews issue 12: CD004415 Lebwohl M, Swanson N, Anderson LL et al. (2012) Ingenol mebutate gel for actinic keratosis. New England Journal of Medicine 366: 1010–19 Leo Laboratories (...) Actinic keratosis: ingenol mebutate gel (ESNM14) Actinic k Actinic ker eratosis: ingenol mebutate gel atosis: ingenol mebutate gel Evidence summary Published: 19 March 2013 nice.org.uk/guidance/esnm14 pathways Ov Overview erview The content of this evidence summary was up-to-date in March 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Key points from the evidence Ingenol mebutate gel (Picato

2013 National Institute for Health and Clinical Excellence - Advice

94. Ingenol Mebutate Gel (Picato): A Novel Agent for the Treatment of Actinic Keratoses Full Text available with Trip Pro

Ingenol Mebutate Gel (Picato): A Novel Agent for the Treatment of Actinic Keratoses Ingenol mebutate gel (Picato) for actinic keratoses.

2014 Pharmacy and Therapeutics

95. Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses

Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Protocols (...) for Painless Photodynamic Therapy (PDT) of Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02124733 Recruitment Status : Recruiting First Posted : April 28, 2014 Last Update Posted : January 26, 2018 See

2014 Clinical Trials

96. Daylight photodynamic therapy for actinic keratoses: A randomized double-blinded non-sponsored prospective study comparing BF-200 aminolevulinic acid with methyl-5-aminolaevulinate. (Abstract)

Daylight photodynamic therapy for actinic keratoses: A randomized double-blinded non-sponsored prospective study comparing BF-200 aminolevulinic acid with methyl-5-aminolaevulinate. Daylight-mediated photodynamic therapy (DL-PDT) using methyl-5-aminolaevulinate (MAL) is effective for thin, grade I, actinic keratoses (AK). There are no published studies of other photosensitizers used in DL-PDT.To compare the efficacy and adverse effects of 5-aminolaevulinic acid nanoemulsion (BF-200 ALA

2014 The British journal of dermatology Controlled trial quality: uncertain

97. Treatment monitoring of topical ingenol mebutate in actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy: a case series. (Abstract)

Treatment monitoring of topical ingenol mebutate in actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy: a case series. 25070046 2015 12 18 2015 03 17 1365-2133 172 3 2015 Mar The British journal of dermatology Br. J. Dermatol. Treatment monitoring of topical ingenol mebutate in actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy: a case series. 816-8 10.1111/bjd.13304 Maier T T (...) Department of Dermatology and Allergology, University Hospital of Munich, Frauenlobstraße 9-11, D-80337, Munich, Germany. Cekovic D D Ruzicka T T Sattler E C EC Berking C C eng Letter 2015 01 22 England Br J Dermatol 0004041 0007-0963 0 3-ingenyl angelate 0 Dermatologic Agents 0 Diterpenes IM Administration, Cutaneous Dermatologic Agents administration & dosage Diterpenes administration & dosage Female Humans Keratosis, Actinic drug therapy Male Microscopy, Confocal Tomography, Optical Coherence 2014 7

2014 British Journal of Dermatology

98. Topical corticosteroid reduces inflammation without compromising efficacy of photodynamic therapy for actinic keratoses a randomised clinical trial. (Abstract)

Topical corticosteroid reduces inflammation without compromising efficacy of photodynamic therapy for actinic keratoses a randomised clinical trial. Photodynamic therapy (PDT) is an effective and established treatment for actinic keratoses (AK) and nonmelanoma skin cancer. The main side-effects of PDT are post-treatment erythema and oedema, and pain during illumination. Severe erythema after PDT enhances the down time associated with the treatment.To evaluate in a randomized intraindividual

2014 The British journal of dermatology Controlled trial quality: uncertain

99. A randomized, double-blind, placebo-controlled clinical trial evaluating Dermytol(®) cream for the treatment of actinic keratoses. Full Text available with Trip Pro

A randomized, double-blind, placebo-controlled clinical trial evaluating Dermytol(®) cream for the treatment of actinic keratoses. Actinic keratosis lesions (AKs) have the potential to develop into squamous cell carcinoma (SCC) and thus therapies to prevent SCC development from AKs are warranted. The aim of this study was to assess the effects of a 3 month application of a canola phenolic acid-based cream (CPA) on AK lesions.This was a randomized, double-blind, placebo-controlled, 12 week

2014 Clinical, cosmetic and investigational dermatology Controlled trial quality: predicted high

100. Lack of activity of betulin-based Oleogel-S10 in treatment of actinic keratoses: A randomized, multicenter, placebo controlled double-blind phase II trial. (Abstract)

Lack of activity of betulin-based Oleogel-S10 in treatment of actinic keratoses: A randomized, multicenter, placebo controlled double-blind phase II trial. Betulinic acid and other triterpenes have shown strong antitumour activity in vitro and in vivo. A triterpene extract of birch bark formed the base of Oleogel-S10 and allowed topical application. Two previous trials have shown efficacy and tolerability in the treatment of actinic keratoses (AKs) with betulin-based Oleogel-S10.To confirm

2014 The British journal of dermatology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>